Explore
Settings

Settings

×

Reading Mode

Adjust the reading mode to suit your reading needs.

Font Size

Fix the font size to suit your reading preferences

Language

Select the language of your choice. NewsX reports are available in 11 global languages.
we-woman
Advertisement

Mankind Pharma Q2 Profit Soars 30% To Rs 653 Crore

 India's Mankind Pharma reported a stronger-than-expected profit for the second quarter of FY24, driven by higher demand for its medications targeting long-term health conditions like diabetes and cardiovascular diseases.

Mankind Pharma Q2 Profit Soars 30% To Rs 653 Crore

 India’s Mankind Pharma reported a stronger-than-expected profit for the second quarter of FY24, driven by higher demand for its medications targeting long-term health conditions like diabetes and cardiovascular diseases.

For the quarter ending September 30, the company’s consolidated net profit reached Rs 653 crore ($77.7 million), marking a 30% increase compared to the same period last year. This figure exceeded analysts’ estimates, which had forecasted a profit of Rs 590 crore, according to LSEG data.

The growth was fueled by a rise in revenue from its key chronic illness drugs segment, which now accounts for 35% of total revenue, up from 34% last year. This increase contributed to an overall 14% revenue growth for the quarter.

Mankind Pharma, which also produces Manforce condoms and Prega News pregnancy kits, continues to benefit from the steady demand for its diverse product portfolio.

mail logo

Subscribe to receive the day's headlines from NewsX straight in your inbox